Indications
Zerene is indicated for the treatment of patients with insomnia who have difficulty falling asleep. It is indicated only when the disorder is severe, disabling or subjecting the individual to extreme distress.
Composition
- Active substance
- zaleplon
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zerene
- Active substance
- zaleplon
- ATC code
- N05CF03
- Group
- Nervous system
- Therapeutic area
- Sleep Initiation and Maintenance Disorders
- Marketing authorisation holder
- Meda AB
- Status
- Withdrawn
- EU authorisation
- 12 Mar 1999